-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Johnson & Johnson released preliminary data from the Phase 1 CHRYSALIS trial of Rybrevant (amivantamab) for the treatment of mesenchymal epithelial transformation (MET) exon 14 (METex14) mutations in non-small cell lung cancer (NSCLC) patients
The preliminary detailed results of the trial will be published in the form of an oral report at the 2021 World Lung Cancer Conference (WCLC) held by the International Association for the Study of Lung Cancer (IASLC) from September 8th to 14th
"The latest advances in the treatment of non-small cell lung cancer have provided benefits to patients with METex14 mutations, but because these therapies are only effective for a limited time, patients will eventually find themselves in need of new treatments," the co-chair of the American Oncology Thoracic Project and Research investigator Alexander Spira, MD, said, “We look forward to sharing the latest research results of amivantamab.
In the phase 1 CHRYSALIS trial, 19 patients with METex14 mutation in the METex14 group received an intravenous injection of 1050 mg of RYBREVANT (patients with a body weight <80 kg) or 1400 mg (patients with a body weight ≥ 80 kg)
The median time to first response for patients averaged 4.
The active pharmaceutical ingredient of Rybrevant is amivantamab, which is a fully human EGFR-mesenchymal epidermal transforming factor (MET) bispecific antibody with immune cell targeting activity, targeting those that carry activated and drug-resistant EGFR and MET mutations and amplifications Tumor
Rybrevant's approval in the United States is based on a clinical trial involving 81 patients
Previously, Rybrevant has been included as a breakthrough treatment product by the National Food and Drug Administration (NMPA) of China.
Reference source: Janssen Presents Phase 1 Results for RYBREVANT (TM) (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
